Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 7
Second-Line LR- MDS Setting: Treatment Options and Considerations
Panelists discuss how they determine thresholds for changing therapy in patients with MDS, evaluate second-line treatment options including the potential use of ESAs after luspatercept, and offer key takeaways for community colleagues managing similar clinical scenarios.
Video content above is prompted by the following:
- What is your threshold for changing therapy in your clinical practice?
- What treatment options would you consider in the second-line setting for this patient? Do you consider trialing ESAs post luspatercept?
- What are some key takeaways you can offer community colleagues from this clinical scenario and discussion?
Related Content:
